TMEM118 Blocking Peptide
- Known as:
- TMEM118 Blocking Peptide
- Catalog number:
- 33r-3736
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- TMEM118 Blocking Peptide
Related genes to: TMEM118 Blocking Peptide
- Gene:
- RNFT2 NIH gene
- Name:
- ring finger protein, transmembrane 2
- Previous symbol:
- TMEM118
- Synonyms:
- FLJ14627
- Chromosome:
- 12q24.22
- Locus Type:
- gene with protein product
- Date approved:
- 2006-01-23
- Date modifiied:
- 2014-11-19
Related products to: TMEM118 Blocking Peptide
Related articles to: TMEM118 Blocking Peptide
- Triple-negative breast cancer (TNBC) is a subtype of breast cancer, and has a high recurrence rate. RING finger transmembrane-domain containing protein 2 (RNFT2) is a RING-finger E3 ubiquitin ligase that exerts oncogene functions in multiple malignant tumors such as bladder cancer and gastric cancer. However, RNFT2's role in TNBC is still unclear. Here, we investigated RNFT2's function and mechanism in TNBC. RNFT2 expressions in different stages of breast cancer were evaluated using the Gene Expression Profiling Interactive Analysis database. Overall survival (OS) in TNBC patients with high RNFT2 expressions was assessed with the Kaplan-Meier plotter database. Meanwhile, RNFT2 expressions in TNBC cells and tissues were determined using Western blot and quantitative real-time PCR. The relationship between RNFT2 and TNBC patients' OS rates was examined with Kaplan-Meier curve analysis. The correlation between RNFT2 expressions and TNBC clinicopathological data was estimated by the chi-square test. Moreover, RNFT2 functions in TNBC were determined using loss-of-function assay, Cell Counting Kit-8 analysis, Transwell, and tube formation assay. Furthermore, RNFT2's mechanism in TNBC was evaluated by prediction software, dual-luciferase reporter assay, and rescue experiments. Additionally, RNFT2's roles in TNBC in vivo were identified with cell-derived xenograft, hematoxylin-eosin staining, and immunohistochemical assays. RNFT2 was elevated in breast cancer, and owned different degrees of overexpression in breast cancer at different stages. Meanwhile, OS of TNBC patients with high RNFT2 expressions was poor. Also, RNFT2 expressions were positively correlated with size, TNM stage, and lymph node metastasis of TNBC. Functionally, silencing RNFT2 repressed TNBC cell proliferation, invasion, and angiogenesis. Mechanistically, miR-211-5p targeted RNFT2, and RNFT2 was negatively regulated by miR-211-5p in TNBC cells. Rescue assays further validated that miR-211-5p overexpression restrained TNBC cell proliferation, invasion, and angiogenesis, yet these impacts were abolished after RNFT2 overexpression. Meanwhile, animal experimental data further implied that RNFT2 knockdown reduced TNBC cell proliferation in vivo. RNFT2 facilitated TNBC development and predicted its adverse outcomes. - Source: PubMed
Publication date: 2025/07/09
Tang ShiWen PeiqiChen YuanyuanLi KaihengDeng JiehuaChen JinghuiLai Lianghai - Excellent biomarkers for predicting survival or therapeutic targets are still lacking in gastric cancer (GC), which is one of the most common causes of cancer-related death worldwide. Ring finger protein, transmembrane 2 (RNFT2), which has been reported to be involved in proteolytic process, but how it functions in tumors is rarely investigated. In the present study, we explored the biological property of RNFT2 in GC, we found that RNFT2 was significantly upregulated in GC, and could serve as a tumor marker to predict prognosis. A series of in vitro cell function experiments were performed, we found that knockdown of RNFT2 expression in GC cells could inhibit cell invasion, migration and proliferation. Besides, in vivo experiments also showed that silencing RNFT2 expression in gastric cancer cells significantly reduced tumor size. Furthermore, through gene set enrichment analysis (GSEA) and immunoblotting studies, we observed that RNFT2 might influence the proliferation, invasion and migration of GC cells through the mTORC1 signaling pathway. In summary, our results clarified the carcinogenic role of RNFT2 in GC progression, provided inspiration to further understand the molecular mechanism of GC and made RNFT2 as a potential target for GC diagnosis and therapy. - Source: PubMed
Publication date: 2025/03/18
Wang YounanMa QianyunZhu ZeyuSang HuaimingFan HaoLi Zhipeng - An important stage in controlling gene expression is RNA alternative splicing (AS), and aberrant AS can trigger the development and spread of malignancies, including hepatocellular carcinoma (HCC). A crucial component of AS is cleavage and polyadenylation-specific factor 4 (CPSF4), a component of the CPSF complex, but it is unclear how CPSF4-related AS molecules describe immune cell infiltration in the total tumor microenvironment (TME). - Source: PubMed
Publication date: 2023/08/05
Yuemaierabola AnwaierGuo JunSun LiliYeerkenbieke BuerlanLiu FuzhongYe DilinaerZhai XiaoyiGuo WenjiaCao Yan - Single-nucleotide polymorphisms (SNPs) in N6-methyladenosine (m6A) related genetic locus play significant roles in tumorigenesis and development. The expression level of many oncogenes and tumour suppressor genes changed because of m6A-associated SNPs. In addition, the relationship between m6A-SNP and bladder cancer (BCa) has not been well studied. - Source: PubMed
Publication date: 2022/10/05
Lv JianchengSong QiangBai KexinHan JieYu HaoLi KaiZhuang JuntaoYang XiaoYang HaiweiLu Qiang - Pharmacogenetic studies in asthma cohorts, primarily made up of White people of European descent, have identified loci associated with response to inhaled beta agonists and corticosteroids (ICSs). Differences exist in how individuals from different ancestral backgrounds respond to long-acting beta agonist (LABA) and ICSs. Therefore, we sought to understand the pharmacogenetic mechanisms regulating therapeutic responsiveness in individuals of African descent. - Source: PubMed
Publication date: 2021/11/09
Ortega Victor EDaya MichelleSzefler Stanley JBleecker Eugene RChinchilli Vernon MPhipatanakul WandaMauger DaveMartinez Fernando DHerrera-Luis EstherPino-Yanes MariaHawkins Gregory AAmpleford Elizabeth JKunselman Susan JCox CoreyBacharier Leonard BCabana Michael DCardet Juan CarlosCastro MarioDenlinger Loren CEng CelesteFitzpatrick Anne MHolguin FernandoHu DongleiJackson Daniel JJarjour NizarKraft MonicaKrishnan Jerry ALazarus Stephen CLemanske Robert FLima John JLugogo NjiraMak AngelMoore Wendy CNaureckas Edward TPeters Stephen PPongracic Jacqueline ASajuthi Satria PSeibold Max ASmith Lewis JSolway JulianSorkness Christine AWenzel SallyWhite Steven RBurchard Esteban GBarnes KathleenMeyers Deborah AIsrael ElliotWechsler Michael E